CJC-1295 (Mod GRF 1-29) Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about CJC-1295 (Mod GRF 1-29) dosing: protocols, safety, and where to buy.
Dose Range
Without DAC: 100-300 mcg subcutaneous 1-3x daily (typically pre-bedtime); With DAC: 1000-2000 mcg subcutaneous once weekly
Frequency
1–3 times daily, typically before bed and/or upon waking
Cycle Length
8–16 weeks; can be used long-term with periodic breaks
Half-Life
~30 minutes (without DAC / MOD-GRF 1-29); ~6-8 days (with DAC, due to covalent albumin binding)
Administration Routes
Quick Reconstitution Calculator
Calculate syringe units instantly
Syringe Draw
10.0 units
2500 mcg/ml · 0.100 ml draw
For laboratory research use only. This tool performs reconstitution math (concentration and syringe-unit conversion) and is not dosing guidance for humans or animals.
Dosing Protocols
Entry protocol — first MOD-GRF 1-29 cycle
Goal: Establish tolerance, detect side effects, track subjective effect, confirm sourcing.
Prerequisites
- Baseline IGF-1 (target: mid-normal range for your age; if already high-normal, reconsider)
- Baseline fasting glucose and HbA1c
- Age-appropriate cancer screening up to date
- Vendor COA confirming ≥98% purity, correct sequence, endotoxin <1 EU/mg
- Bacteriostatic water 0.9% benzyl alcohol (not sterile water)
- Insulin syringes 29-31G × 1/2" × 0.5 mL
Reconstitution (typical 2 mg vial)
- Add 2 mL BAC → 1 mg/mL = 1000 mcg/mL
- On U-100 insulin syringe: 10 units = 0.1 mL = 100 mcg (target dose)
- See Reconstitution Tool for vial-specific math
Cycle 1 — 12 weeks
Weeks 1-2: tolerance
- 100 mcg MOD-GRF 1-29 SC, pre-bed, daily (fasted, 2+ hours after dinner)
- No stack yet — isolate tolerance
- Track: injection-site reaction, flushing, sleep quality, energy, any numbness/tingling
Weeks 3-12: add ipamorelin
- 100 mcg MOD-GRF 1-29 + 200 mcg ipamorelin — single combined injection, pre-bed
- Or dose twice daily: AM fasted + pre-bed (same doses each)
- Track: body composition (tape measure or DEXA), sleep architecture, recovery from training
What to expect
- Week 1-2: Mild flushing, possible vivid dreams, may feel more rested in AM
- Week 3-6: Improved sleep depth, better recovery from training, possible modest fat loss
- Week 7-12: Body composition changes (tape/DEXA if tracked), sustained energy improvement
- If nothing: Re-examine sourcing (COA), reconstitution technique, or meal timing (postprandial blunting)
Labs at 12 weeks
- IGF-1 (target: upper-normal for age, not supraphysiologic)
- Fasting glucose, HbA1c
- Comprehensive metabolic panel
Decision at 12 weeks
- IGF-1 in range + benefit + no side effects → continue
- IGF-1 >upper normal → reduce dose or frequency
- Persistent side effects → reduce dose or stop
- No benefit → stop and re-evaluate (or switch to DAC variant for trial)
Red flags — stop
- Persistent numbness/tingling (carpal tunnel signal)
- Fasting glucose rising above 100 mg/dL
- New joint swelling or pain
- Any new palpable lump or lymphadenopathy
Intermediate protocol — month 3-12
Assumes successful first cycle, no adverse events, baseline IGF-1 appropriately risen, consistent benefit.
Standard maintenance
- MOD-GRF 1-29 100 mcg + Ipamorelin 200 mcg combined SC
- Twice daily: AM fasted + pre-bed
- Fasted state (2+ hours post-meal) for both doses
- Consistent timing day-to-day
Advanced dosing (if benefit plateaus and IGF-1 remains in range)
- Add third daily dose: pre-workout (30-60 min before training, fasted)
- Stay at 100 mcg MOD-GRF per dose — do NOT escalate single-dose above 100 mcg (no additional GH pulse, just more side effects)
- Ipamorelin ceiling: 300 mcg per dose (above this, cross-desensitization of ghrelin receptor)
Pairing additions
- BPC-157 250 mcg BID SC for tendon/joint recovery if training hard
- Creatine 5 g/day oral (independent anabolic)
- Vitamin D3 5000 IU + K2 MK-7 100 mcg
- Magnesium glycinate 400 mg pre-bed (synergistic sleep)
- Protein 1.6-2.2 g/kg/day (substrate for GH-mediated protein synthesis)
Monitoring cadence
- IGF-1 quarterly for first year, then biannually
- Fasting glucose and HbA1c quarterly
- CMP biannually
- Symptom diary (monthly self-check for carpal tunnel, edema, joint stiffness)
- Body composition (DEXA or tape) every 3-6 months
Dose adjustments
- IGF-1 too high (>upper normal for age) → reduce to once-daily or reduce per-dose to 75 mcg
- Glucose rising → reduce dose, increase cardio, evaluate diet
- Persistent side effects → reduce dose 25%, reassess in 4 weeks
Cycling considerations
- Continuous daily use is reasonable for 6-12 months with monitoring
- Some clinicians prefer 5-days-on / 2-days-off to preserve pulsatile nature
- 4-6 weeks off annually is a conservative cycle
When to pause or stop
- Any new malignancy diagnosis → stop immediately
- New diabetic retinopathy → stop
- Pregnancy desire (for women) → stop 3 months before attempting conception
- Unexplained elevated IGF-1 beyond age-appropriate upper limit
Advanced protocol — established users, longitudinal optimization
Assumes 12+ months of uneventful use, consistent IGF-1 monitoring, documented benefit.
Dose and frequency
- MOD-GRF 1-29 100 mcg + Ipamorelin 200-300 mcg
- 2-3x daily (AM fasted, optional pre-workout, pre-bed)
- Consistent timing and injection technique
Precision tuning
- Target IGF-1: 75th percentile for age — high-normal, not above
- Escalate/de-escalate by 25% dose steps at 8-week intervals based on IGF-1 + subjective response
- Do not exceed 400 mcg total MOD-GRF 1-29 daily (dose-response flattens; side effects accumulate)
Rotational strategies
- 12 weeks on / 4 weeks off quarterly to preserve somatotroph sensitivity
- Or 6 months on / 1 month off biannually
- Re-titrate after breaks
Comprehensive stack example
- AM fasted: MOD-GRF 100 mcg + Ipamorelin 200 mcg SC
- Pre-workout: same
- Pre-bed: same
- BPC-157 250 mcg BID
- TB-500 2 mg weekly (sports injury support)
- NAD+ precursor 500 mg daily
- Testosterone replacement (if clinically indicated and supervised)
- Vitamin D, K2, magnesium, omega-3s, creatine
Advanced monitoring
- IGF-1 and IGFBP-3 quarterly
- Fasting insulin, HOMA-IR annually
- hs-CRP, IL-6 annually
- Comprehensive cancer screening per age (colonoscopy, mammography/prostate, skin)
- Echocardiogram every 2-3 years if continuous use >3 years (conservative, no evidence of cardiotoxicity at physiologic IGF-1)
- DEXA body composition annually
What advanced users should NOT do
- Chase higher and higher IGF-1 ("more is better" mentality)
- Stack with exogenous rhGH simultaneously
- Combine with other growth-promoting agents (IGF-1 LR3, MGF) — safety envelope breaks
- Skip cancer screening ("I feel fine")
- Dose above 400 mcg total MOD-GRF 1-29 daily
- Continue through any malignancy workup
Consider stopping
- Any new cancer diagnosis
- New diabetes with progressive HbA1c elevation
- Pregnancy planning
- Unexplained organomegaly or acromegaly-like features (very rare at physiologic dosing)
- Loss of benefit for 6+ months despite appropriate IGF-1
Honest assessment
MOD-GRF 1-29 at properly calibrated physiologic doses is one of the better-tolerated GH-axis interventions. It does not replicate exogenous rhGH's dramatic body-composition effects, but it also carries a better safety profile because endogenous feedback remains intact. Long-term (>3 year) data remains limited; users should proceed with consistent monitoring and a willingness to stop.
Weight-Based Dosing
Commonly Stacked With
Essential pairing: Ipamorelin
MOD-GRF 1-29 is rarely dosed alone in modern protocols. The canonical stack is:
- MOD-GRF 1-29 100 mcg + Ipamorelin 200 mcg — single combined SC injection
- 1-3 times daily: pre-bed (most important), optional AM fasted, optional pre-workout
- Produces 3-5x greater GH pulse than either alone
- See Ipamorelin compound page for pharmacology
Alternative ghrelin-receptor partners
- Hexarelin 100 mcg — more potent GH release but raises cortisol and prolactin; not preferred
- MK-677 (ibutamoren) 10-25 mg oral — daily instead of injection; produces sustained (non-pulsatile) GH; different profile
- GHRP-2 or GHRP-6 100-200 mcg — older generation; raises appetite (GHRP-6) or has milder profile (GHRP-2)
Recovery and repair pairings
- BPC-157 250-500 mcg/day SC — independent tissue healing; no pharmacokinetic conflict. See BPC-157 compound page.
- TB-500 / Thymosin beta-4 2-10 mg/week — tendon/ligament recovery; often stacked for sports injury.
Body composition pairings
- Tesamorelin (FDA-approved GHRH analog) — higher potency, prescription-only, FDA-approved for HIV-associated lipodystrophy; not typically stacked with MOD-GRF 1-29 (redundant)
- Testosterone replacement (clinician-supervised only) — independent anabolic axis; combine with care
- Cardarine (GW-501516) / SR9009 — research chemicals; not recommended due to insufficient long-term safety data
Stacks to avoid
- CJC-1295 DAC + MOD-GRF 1-29 simultaneously — redundant GHRH receptor activity; one or the other, not both
- Multiple GHRPs together (e.g., ipamorelin + hexarelin) — no evidence of benefit, additive side effects
- High-dose exogenous rhGH + secretagogues — defeats the purpose; use one pathway
- Any GH-raising agent during active malignancy — IGF-1 concern
Timing with meals
- Administer in fasted state (at least 2 hours post-carbohydrate meal)
- Postprandial somatostatin tone blunts GH response by 30-70%
- Pre-bed dose ideally 2+ hours after last meal
- AM dose ideally on waking, before breakfast
Timing with exercise
- Pre-workout dosing (30-60 min before) may amplify training-induced GH response
- Post-workout dosing is acceptable but theoretically less optimal (postprandial somatostatin from carb replenishment)
Cycling
- Sermorelin extrapolation suggests continuous daily use is safe for 6-12 months with proper monitoring
- Some clinicians use 5 days on / 2 days off to preserve sensitivity
- Annual re-assessment of IGF-1 and clinical benefit is appropriate
Related Compounds — Deeper Research Paths — CJC-1295 (Mod GRF 1-29) is the most-used GHRH analog. Close siblings: CJC-1295 DAC (longer-acting variant), Sermorelin (older GHRH), Tesamorelin (visceral-fat specific GHRH). GH secretagogue (GHRP) pairing partners activating the ghrelin receptor: Ipamorelin (most selective, preferred pair — see CJC-1295 + Ipamorelin blend), GHRP-2, GHRP-6, Hexarelin, MK-677 (oral, non-peptide). Downstream effects amplify with IGF-1 LR3. Fat-loss GH stacking: AOD-9604, HGH Fragment 176-191.
Side Effects & Safety
Contraindications
**Absolute contraindications** - **Active malignancy of any type** — GH/IGF-1 axis stimulation is theoretically pro-tumorigenic; substantive epidemiologic signal for prostate, colorectal, and premenopausal breast cancer ([Renehan et al., 2004](https://pubmed.ncbi.nlm.nih.gov/15110491/)) - **Diabetic retinopathy (active or history)** — IGF-1 promotes retinal neovascularization - **Pregnancy and lactation** — no safety data, GH axis alterations during pregnancy have unknown consequences - **Children with open growth plates** — unintended longitudinal growth - **Critical illness requiring ICU care** — exogenous GH increased mortality in critically ill patients ([Takala et al., 1999, *NEJM*]) **Relative contraindications (clinician-guided)** - History of cancer within 5 years — individualize risk/benefit with oncology - Type 2 diabetes with poor control (HbA1c >8) — GH worsens insulin resistance - Severe hypothyroidism — suboptimal GH response; optimize thyroid first - Intracranial pathology / elevated ICP — theoretical concern with GH - Obstructive sleep apnea — GH may exacerbate upper-airway soft tissue **Drug interactions** - **Glucocorticoids (prednisone, dexamethasone)** — blunt GHRH response; minimize if possible - **Somatostatin analogs (octreotide, lanreotide)** — direct GH suppression; incompatible use - **Insulin and insulin secretagogues** — GH is counter-regulatory; monitor glucose - **Oral estrogens (high-dose)** — blunt hepatic IGF-1 response - **Chemotherapy agents** — avoid concurrent use during active chemo **Surgery and procedure considerations** - Hold for 1-2 weeks before elective major surgery (conservative) - Disclose use to all clinicians, particularly oncology, ophthalmology, endocrinology - Not a concern for routine procedures (dental, dermatologic) **Disclosure obligations** - All clinicians, especially oncology, ophthalmology, endocrinology - Insurance and life-insurance applications (material in some jurisdictions) - Anti-doping: GH-releasing peptides are WADA-prohibited at all times — not appropriate for competitive athletes subject to testing
Additional Notes
Standard dose: 100 mcg SC per injection
- Most protocols use 100 mcg per dose regardless of dose frequency
- Increasing per-dose above 100 mcg does not meaningfully increase GH pulse (receptor saturation) but adds side effects
- Frequency scales effect: 1x/day < 2x/day < 3x/day
Dose frequency tiers
| Frequency | Use case | IGF-1 elevation |
|---|---|---|
| 100 mcg pre-bed only | Beginner, sleep-focused | Modest |
| 100 mcg AM + PM | Standard protocol | Moderate |
| 100 mcg 3x/day | Body composition focus | Maximum physiologic |
| 200 mcg single dose | NOT recommended | Receptor-saturated; wasted dose |
Timing with meals
- Fasted state (2+ hours post-carb meal) — essential
- Postprandial somatostatin blunts GH pulse by 30-70%
- Pre-bed: at least 2 hours after dinner
- AM: immediately on waking before any food
Timing with exercise
- Pre-workout (30-60 min before) amplifies training-induced GH
- Post-workout less optimal (protein/carb meals raise somatostatin)
- If only one dose per day, pre-bed > pre-workout > AM
Injection route
- Subcutaneous only (IM has no pharmacokinetic advantage)
- Lower abdomen, thigh, or upper arm; rotate sites
- 29-31G insulin needle
Storage
- Lyophilized: -20°C (freezer) ideal; refrigerated (2-8°C) acceptable for short term
- Reconstituted: refrigerated 2-8°C; use within 28 days
- Do NOT freeze reconstituted solution
- Protect from light
What NOT to do
- Do not dose in the morning after breakfast (wasted dose)
- Do not exceed 100 mcg per injection (no added benefit, more side effects)
- Do not mix with DAC variant in same protocol (redundant)
- Do not skip fasting window (severely blunts response)
Where to Buy CJC-1295 (Mod GRF 1-29)
Compare 6 listings across 4 vendors, from $29.00
Frequently Asked Questions
What is the recommended CJC-1295 (Mod GRF 1-29) dosage?
The typical dose range for CJC-1295 (Mod GRF 1-29) is Without DAC: 100-300 mcg subcutaneous 1-3x daily (typically pre-bedtime); With DAC: 1000-2000 mcg subcutaneous once weekly. It is usually administered 1–3 times daily, typically before bed and/or upon waking. Always start with the lowest effective dose.
How often should I take CJC-1295 (Mod GRF 1-29)?
1–3 times daily, typically before bed and/or upon waking
Does CJC-1295 (Mod GRF 1-29) need to be cycled?
Yes, typical cycle length is 8–16 weeks; can be used long-term with periodic breaks.
What are CJC-1295 (Mod GRF 1-29) side effects?
**Expected / benign** - **Injection-site reaction** — mild redness, itching, small bump; 24-48 hour resolution - **Facial flushing / warmth** 15-30 min post-injection (histamine release from GHRH action); typically diminishes after week 1-2 - **Mild nausea** in first week at higher doses - **Transient hunger increase** (less than with MK-677 or ghrelin agonists) **Dose-dependent** - **Water retention / mild peripheral edema** — common in first 2-4 weeks, usually resolves - **Tingling or numbness in hands / carpal tunnel symptoms** — dose-related; if persistent, reduce dose - **Morning lethargy or grogginess** — from sub-optimal GH pulse timing; adjust to pre-bed dosing - **Joint stiffness** — particularly in knees and fingers; dose-responsive - **Elevated fasting glucose** — GH is counter-regulatory to insulin; modest at physiologic doses **Uncommon** - **Headache** — usually resolves with dose reduction or improved hydration - **Dizziness or orthostatic hypotension** — rare - **Dream vividness** — common with pre-bed dosing - **Injection-site lipodystrophy** — with repeated same-site injection; rotate sites **Serious (dose- and duration-dependent)** - **Insulin resistance / impaired glucose tolerance** — chronic supraphysiologic GH elevation; rare at proper MOD-GRF 1-29 dosing but more common with DAC variant or MK-677 - **Acromegaly-like features** — not reported at physiologic doses; theoretical at very high chronic dosing - **Potential malignancy risk** — see IGF-1 cancer meta-analysis ([Renehan et al., 2004](https://pubmed.ncbi.nlm.nih.gov/15110491/)). Elevated IGF-1 is epidemiologically associated with increased prostate, colorectal, and premenopausal breast cancer risk - **Carpal tunnel syndrome** — dose-responsive, typically reversible with dose reduction **Absolute contraindications** - Active malignancy (any type) — GH/IGF-1 signaling may promote tumor growth - History of cancer within 5 years — insufficient data to stratify risk - Diabetic retinopathy — IGF-1 promotes retinal neovascularization - Pregnancy and lactation — no safety data - Children with open growth plates — unintended growth acceleration **Relative contraindications** - Type 2 diabetes with poor control (HbA1c >8) — glucose worsening risk - Severe hypothyroidism — suboptimal GH axis function; optimize thyroid first - Intracranial pathology / elevated ICP — theoretical concern - Active autoimmune disease — no direct evidence of harm, but insufficient data **Drug interactions** - **Glucocorticoids** — suppress GHRH response; minimize if possible - **High-dose SSRIs / antipsychotics** — may blunt GH response - **Insulin / insulin secretagogues** — GH raises glucose; monitor **Lab monitoring** - IGF-1 baseline and 8-12 weeks after starting - Fasting glucose and HbA1c quarterly for first year, then annually - Age-appropriate cancer screening per USPSTF guidelines (no different from non-users)
Where can I buy CJC-1295 (Mod GRF 1-29)?
Compare 6 listings from 4 vendors on our price comparison page, starting from $29.00.
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.